Pulike Biological Engineering Cash Flow Conversion Efficiency
Pulike Biological Engineering cash flow conversion efficiency. Based on the latest financial reports, Pulike Biological Engineering (603566) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥87.38 Million ≈ $12.79 Million USD) by net assets (CN¥2.58 Billion ≈ $377.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Pulike Biological Engineering (2010–2024)
Cash flow conversion efficiency of Pulike Biological Engineering from 2010 to 2024. This chart illustrates how Pulike Biological Engineering's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Pulike Biological Engineering stock price today for real-time trading data and today's change.
Pulike Biological Engineering Cash Flow Conversion Ratio Explained
Pulike Biological Engineering cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Pulike Biological Engineering Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulike Biological Engineering ranked by their cash flow conversion efficiency. Also see Pulike Biological Engineering (603566) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
B+S GROUP SA INH EO-06
F:70B
|
N/A |
|
Emeco Holdings Ltd
AU:EHL
|
0.189x |
|
Cantor Equity Partners IV, Inc. Class A Ordinary Shares
NASDAQ:CEPF
|
0.000x |
|
Hanwha General
KO:000370
|
0.202x |
|
Taiwan Shin Kong Security Co Ltd
TW:9925
|
0.029x |
|
Keystone Realtors Limited
NSE:RUSTOMJEE
|
-0.075x |
|
Aberdeen Standard Global Infrastructure Income Fund
NYSE:ASGI
|
N/A |
|
Shenzhen Jiawei Photovoltaic Lighting Co Ltd
SHE:300317
|
0.015x |
Annual Cash Flow Conversion Efficiency for Pulike Biological Engineering (2010–2024)
The table below shows the annual cash flow conversion efficiency of Pulike Biological Engineering from 2010 to 2024. Review how much free cash does Pulike Biological Engineering generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.63 Billion ≈ $384.28 Million |
CN¥268.79 Million ≈ $39.33 Million |
0.102x | -1.41% |
| 2023-12-31 | CN¥2.72 Billion ≈ $398.59 Million |
CN¥282.78 Million ≈ $41.38 Million |
0.104x | +27.22% |
| 2022-12-31 | CN¥2.80 Billion ≈ $409.51 Million |
CN¥228.36 Million ≈ $33.42 Million |
0.082x | -30.87% |
| 2021-12-31 | CN¥1.80 Billion ≈ $263.46 Million |
CN¥212.53 Million ≈ $31.10 Million |
0.118x | -22.92% |
| 2020-12-31 | CN¥1.71 Billion ≈ $250.17 Million |
CN¥261.83 Million ≈ $38.31 Million |
0.153x | +81.24% |
| 2019-12-31 | CN¥1.66 Billion ≈ $242.62 Million |
CN¥140.10 Million ≈ $20.50 Million |
0.084x | +9.45% |
| 2018-12-31 | CN¥1.64 Billion ≈ $239.34 Million |
CN¥126.27 Million ≈ $18.48 Million |
0.077x | -14.02% |
| 2017-12-31 | CN¥1.57 Billion ≈ $229.57 Million |
CN¥140.86 Million ≈ $20.61 Million |
0.090x | -47.45% |
| 2016-12-31 | CN¥1.48 Billion ≈ $216.71 Million |
CN¥253.03 Million ≈ $37.03 Million |
0.171x | +22.12% |
| 2015-12-31 | CN¥1.34 Billion ≈ $195.68 Million |
CN¥187.09 Million ≈ $27.38 Million |
0.140x | -36.75% |
| 2014-12-31 | CN¥683.59 Million ≈ $100.03 Million |
CN¥151.21 Million ≈ $22.13 Million |
0.221x | -26.36% |
| 2013-12-31 | CN¥603.33 Million ≈ $88.29 Million |
CN¥181.21 Million ≈ $26.52 Million |
0.300x | -10.59% |
| 2012-12-31 | CN¥440.47 Million ≈ $64.45 Million |
CN¥147.96 Million ≈ $21.65 Million |
0.336x | -31.46% |
| 2011-12-31 | CN¥311.26 Million ≈ $45.55 Million |
CN¥152.54 Million ≈ $22.32 Million |
0.490x | +35.24% |
| 2010-12-31 | CN¥195.88 Million ≈ $28.66 Million |
CN¥70.98 Million ≈ $10.39 Million |
0.362x | -- |
About Pulike Biological Engineering
Pulike Biological Engineering, Inc. engages in the research, development, production, and sale of veterinary biological products, chemical drugs, and traditional Chinese veterinary drugs. The company offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. Pulike Biological Engineering, Inc. was founded in 1995 and is headquartered in Luoyang, China.